4/6/2010

FDA reviewers voiced concern about suicide and suicide attempts by clinical-trial patients who received Daxas, a drug for chronic obstructive pulmonary disease from Forest Laboratories and Nycomed. Forest said an analysis of the cases "does not suggest a causal relationship" with Daxas, which is also linked to a higher risk of cancer, according to FDA data.

Full Story:
Reuters

Related Summaries